Vatiquinone

Vatiquinone (EPI-743, PTC-743, alpha-tocotrienol quinone) is a synthetic para-benzoquinone structurally derived from the vitamin E tocotrienol family and developed as an orally bioavailable, brain-penetrant cytoprotectant for inherited mitochondrial diseases and Friedreich ataxia. The compound is the oxidized (quinone) form of alpha-tocotrienol, bearing a 2,3,5-trimethyl-1,4-benzoquinone headgroup conjugated through a hydroxylated isoprenoid side chain. Vatiquinone is reduced intracellularly by NAD(P)H:quinone oxidoreductase 1 (NQO1) to its hydroquinone form, which functions as a potent inhibitor of 15-lipoxygenase (15-LO), the rate-limiting enzyme in the ferroptotic cell death cascade that drives lipid peroxidation in mitochondrially compromised neurons and other cell types. This dual mechanism (NQO1-dependent bioactivation followed by 15-LO inhibition) distinguishes vatiquinone from earlier quinone antioxidants such as coenzyme Q10 and idebenone and underwrites a 1,000- to 10,000-fold potency advantage in patient-derived fibroblast assays modeling the oxidative stress of mitochondrial disease.

The compound was discovered at Edison Pharmaceuticals in the late 2000s, received Orphan Drug Designation from the United States Food and Drug Administration for Leigh syndrome and subsequently for Friedreich ataxia, and advanced through open-label Phase 2 studies in Leigh syndrome, Leber hereditary optic neuropathy, and other genetically defined mitochondrial disorders before the program was acquired by PTC Therapeutics in 2019. PTC Therapeutics conducted the registrational MOVE-FA Phase 3 trial (NCT04577352) in 143 patients with Friedreich ataxia aged 7 years and older. The primary endpoint of change from baseline in modified Friedreich Ataxia Rating Scale (mFARS) total score at 72 weeks did not reach statistical significance in the modified intent-to-treat population (treatment difference -1.61 points, p = 0.144). However, a prespecified sensitivity analysis of patients completing the full 72-week course demonstrated a 75 percent slowing of disease progression relative to placebo; the Upright Stability subscale of the mFARS showed a nominally significant treatment effect (-1.26 points, p = 0.021); and the Modified Fatigue Impact Scale showed a nominally significant benefit (-5.05 points, p = 0.025). In the long-term extension study, vatiquinone-treated patients progressed 3.75 points on the mFARS over 36 months compared to 7.48 points in a matched natural history cohort from the Friedreich Ataxia Clinical Outcome Measures Study registry, representing a clinically meaningful 50 percent slowing of disease progression. The FDA accepted the New Drug Application with Priority Review and set a Prescription Drug User Fee Act target date of August 19, 2025, but subsequently issued a Complete Response Letter concluding that the available data did not provide substantial evidence of efficacy and stipulating that an additional adequate and well-controlled clinical trial would be required for resubmission.

Pharmacokinetics are characterized by high lipophilicity, a pronounced food effect (medium-fat meal increases systemic exposure up to 25-fold relative to fasting), CYP3A4-mediated hepatic metabolism, high plasma protein binding (greater than 96 percent), an effective half-life of approximately 9 hours supporting three-times-daily dosing with meals, and predominantly fecal elimination. The compound is generally well tolerated; the principal adverse events in clinical trials have been mild gastrointestinal symptoms and elevations in plasma cholesterol. This monograph reviews the chemistry, synthesis, and structural pharmacology of vatiquinone; the NQO1-mediated bioactivation and 15-lipoxygenase inhibition mechanism; the comprehensive pharmacokinetic record including drug-drug interaction characterization; the preclinical evidence across ferroptosis, mitochondrial disease, and Friedreich ataxia models; the clinical evidence base from Leigh syndrome through MOVE-FA; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative compounds (omaveloxolone, idebenone, coenzyme Q10, elamipretide, nicotinamide riboside) against vatiquinone on five competency standards.